What is Pulmonary Embolism?
Pulmonary embolism (PE) is a serious medical condition that occurs when a blood clot blocks one or more arteries in the lungs, preventing blood flow to lung tissue. Most pulmonary embolisms originate from blood clots in the deep veins of the legs or pelvis, which break loose and travel through the bloodstream to the lungs. This condition affects approximately 600,000 people annually in the United States and can be life-threatening if not treated promptly. Pulmonary embolism can occur at any age but is more common in adults over 40, with risk increasing significantly with age.
Key statistics
| Annual incidence | 1-2 per 1,000 people |
| Mortality rate (untreated) | Up to 30% |
| Mortality rate (treated) | 2-8% |
| Recurrence rate | 5-10% within first year |
Symptoms
Common symptoms include: sudden shortness of breath, chest pain, rapid heart rate, cough (sometimes with blood), leg swelling, anxiety, and lightheadedness.
Early symptoms often develop suddenly and may include mild shortness of breath during exertion, a sense of anxiety or apprehension, and subtle chest discomfort that may worsen with deep breathing.
Common symptoms progress to include sharp, stabbing chest pain that worsens with breathing or coughing, rapid breathing, rapid heart rate (tachycardia), and a dry cough that may produce pink, foamy sputum or blood.
Serious symptoms indicate a large pulmonary embolism and require immediate medical attention: severe shortness of breath at rest, crushing chest pain, fainting or loss of consciousness, blue discoloration of lips or fingernails (cyanosis), cold and clammy skin, and signs of shock including rapid weak pulse and severe drop in blood pressure.
Causes and risk factors
Pulmonary embolism is primarily caused by blood clots that form elsewhere in the body, most commonly in the deep veins of the legs (deep vein thrombosis). These clots break free and travel through the bloodstream to lodge in pulmonary arteries.
Major risk factors include: prolonged immobility (surgery, long flights, bed rest), recent surgery or trauma, cancer and chemotherapy, pregnancy and postpartum period, use of oral contraceptives or hormone replacement therapy, smoking, obesity, and advanced age.
Medical conditions that increase risk include heart failure, chronic obstructive pulmonary disease, inflammatory bowel disease, and inherited blood clotting disorders such as Factor V Leiden mutation, prothrombin gene mutation, and antithrombin III deficiency.
Genetic factors account for approximately 20-25% of cases, with inherited thrombophilia conditions making blood more likely to clot abnormally.
Prevention
Prevention strategies focus on reducing blood clot formation and maintaining healthy circulation. Medical prevention includes use of anticoagulant medications for high-risk patients during surgery or hospitalization, compression stockings during long periods of immobility, and pneumatic compression devices during surgery.
Lifestyle modifications include staying active during long trips by walking every 2 hours or performing calf exercises, maintaining a healthy weight, staying hydrated, not smoking, and exercising regularly to improve circulation.
High-risk individuals should discuss prophylactic anticoagulation with their healthcare provider before surgery or during periods of immobilization. Those with inherited clotting disorders may require long-term anticoagulation therapy.
Complications
Without prompt treatment, pulmonary embolism can lead to life-threatening complications including acute right heart failure, cardiac arrest, and death. Large emboli can cause sudden cardiovascular collapse and require emergency intervention.
Chronic complications may develop in some patients, including chronic thromboembolic pulmonary hypertension (CTEPH), where scar tissue from resolved clots causes persistent high blood pressure in the lungs. This occurs in approximately 2-4% of PE survivors and can lead to progressive right heart failure if untreated.
Post-thrombotic syndrome can affect the legs when deep vein thrombosis preceded the pulmonary embolism, causing chronic pain, swelling, and skin changes. Recurrent pulmonary embolism is also a concern, particularly in patients with underlying risk factors or inadequate anticoagulation.
Diagnosis
Diagnosis of pulmonary embolism requires a combination of clinical assessment, laboratory tests, and imaging studies. Clinical scoring systems such as the Wells score or Geneva score help assess pre-test probability.
Blood tests include D-dimer, which is elevated in most cases but is not specific for PE. Arterial blood gas analysis may show low oxygen levels and other abnormalities.
Imaging studies are crucial for definitive diagnosis. Computed tomography pulmonary angiogram (CTPA) is the gold standard, providing detailed images of pulmonary arteries. Ventilation-perfusion (V/Q) scan is an alternative when CT is contraindicated. Pulmonary angiography, the historical gold standard, is now rarely used due to its invasive nature.
Additional tests may include echocardiogram to assess heart function, chest X-ray (often normal but may show signs of lung damage), and duplex ultrasound of the legs to identify deep vein thrombosis.
Treatment
Treatment focuses on preventing clot extension, reducing embolism recurrence, and preserving lung function. Anticoagulation therapy is the cornerstone of treatment, typically starting with heparin or enoxaparin for immediate anticoagulation, followed by oral anticoagulants such as warfarin, rivaroxaban, apixaban, or dabigatran.
Thrombolytic therapy using medications like alteplase may be considered for massive pulmonary embolism with hemodynamic instability. This treatment carries higher bleeding risks but can rapidly dissolve clots.
Surgical interventions include pulmonary embolectomy for massive PE when thrombolysis is contraindicated or unsuccessful, and inferior vena cava filter placement to prevent future emboli in patients who cannot receive anticoagulation.
Supportive care includes oxygen therapy, pain management, and monitoring for complications. Treatment duration typically ranges from 3 months to lifelong, depending on risk factors and underlying conditions.
Prognosis
With prompt diagnosis and appropriate treatment, the prognosis for pulmonary embolism is generally good. Mortality rates drop significantly from 30% without treatment to 2-8% with proper anticoagulation therapy.
Factors affecting prognosis include the size and location of the embolism, patient age, underlying health conditions, and time to treatment initiation. Patients with small, peripheral emboli typically recover completely, while those with massive central emboli face higher risks of complications and death.
Long-term outlook is favorable for most patients, with full recovery expected within weeks to months. However, some patients may experience persistent shortness of breath or exercise intolerance. The risk of recurrence varies from 5-10% in the first year but can be significantly reduced with appropriate anticoagulation therapy.
Quality of life
Living with pulmonary embolism and its treatment requires several lifestyle adjustments. Activity modification during the acute phase involves gradual return to normal activities as symptoms improve, with most patients able to resume full activity within 2-4 weeks.
Medication management is crucial for those on long-term anticoagulation. This includes regular monitoring of blood levels (for warfarin users), being aware of drug and food interactions, and understanding bleeding precautions.
Diet considerations include maintaining consistent vitamin K intake for warfarin users, staying well-hydrated, and limiting alcohol consumption. Those on newer anticoagulants have fewer dietary restrictions.
Mental health support is important, as many patients experience anxiety about recurrence or complications. Counseling and support groups can help address these concerns and improve coping strategies.
Work accommodations may be needed initially, including modified duties to avoid heavy lifting or prolonged standing, and flexibility for medical appointments and monitoring.
Pregnancy and fertility
Pregnancy significantly increases the risk of pulmonary embolism, with incidence rates 5-6 times higher than in non-pregnant women. The risk is highest in the postpartum period, particularly after cesarean delivery.
Treatment during pregnancy requires special consideration, as warfarin is teratogenic. Heparin or enoxaparin are preferred anticoagulants during pregnancy and breastfeeding.
Fertility considerations include the temporary impact of anticoagulation on conception timing and the need for careful pregnancy planning in women requiring long-term anticoagulation. Genetic counseling may be recommended for women with inherited thrombophilia.
Delivery planning involves coordination between obstetric and hematologic teams to manage anticoagulation around delivery and determine appropriate thromboprophylaxis duration postpartum.
Children
Pulmonary embolism is rare in children but can occur, particularly in those with underlying medical conditions, central venous catheters, or inherited clotting disorders. Pediatric presentation may be more subtle, with symptoms including unexplained tachycardia, tachypnea, or chest pain.
Diagnosis challenges in children include lower clinical suspicion, difficulty obtaining cooperation for imaging studies, and concerns about radiation exposure from CT scans.
Treatment considerations involve weight-based dosing of anticoagulants, careful monitoring for bleeding complications, and attention to the impact on growth and development. School accommodations may be needed for activity restrictions and medical appointments.
When to see a doctor
Seek emergency medical attention immediately for sudden shortness of breath, sharp chest pain that worsens with breathing, coughing up blood, rapid heart rate with lightheadedness, fainting, or signs of shock.
Contact your healthcare provider promptly for new leg swelling or pain, especially if one-sided, persistent cough, gradual worsening of shortness of breath, or any concerning symptoms in high-risk individuals.
Routine follow-up is essential for patients with known risk factors, those on anticoagulation therapy requiring monitoring, or anyone with a personal or family history of blood clots.
Regional context
Limited specific data exists for pulmonary embolism prevalence in the Caucasus region, though genetic studies have identified variations in thrombophilia genes among populations in Georgia, Armenia, and Azerbaijan. Healthcare infrastructure for emergency PE diagnosis and treatment varies across the region, with major medical centers in Tbilisi, Yerevan, and Baku equipped with modern diagnostic capabilities. GMJ welcomes contributions from regional researchers to build the evidence base for pulmonary embolism in the Caucasus.
Research and clinical trials
Current research focuses on developing safer and more effective anticoagulants, improving risk stratification tools, and investigating novel therapeutic approaches. Studies are examining extended duration anticoagulation strategies and identifying optimal candidates for different treatment approaches.
Emerging therapies include new direct oral anticoagulants with improved safety profiles and novel thrombolytic agents with reduced bleeding risk. Research into biomarkers for risk stratification and prognosis continues to advance.
Patients interested in clinical trials can search ClinicalTrials.gov for current studies investigating new treatments for pulmonary embolism and venous thromboembolism.
Frequently asked questions
How long do I need to take blood thinners after a pulmonary embolism?
Treatment duration depends on the underlying cause and risk factors. Patients with provoked PE (clear trigger like surgery) typically require 3-6 months of anticoagulation, while those with unprovoked PE or ongoing risk factors may need longer or indefinite treatment.
Can I fly after having a pulmonary embolism?
Flying is generally safe once you’re stable on anticoagulation therapy, usually after several weeks. Discuss timing with your doctor, wear compression stockings, stay hydrated, and move frequently during flights.
Will I have permanent lung damage?
Most patients recover completely with appropriate treatment. Small areas of lung scarring may occur but typically don’t cause symptoms. Rarely, chronic pulmonary hypertension can develop, requiring specialized treatment.
Is pulmonary embolism hereditary?
While PE itself isn’t directly inherited, genetic clotting disorders increase risk. Family history of blood clots may warrant genetic testing for inherited thrombophilia, especially in young patients or those with recurrent clots.
What activities should I avoid while on blood thinners?
Avoid contact sports and activities with high injury risk. You can generally maintain normal daily activities, but discuss specific concerns with your healthcare provider. Minor cuts may bleed longer, so take appropriate precautions.
Support and resources
International organizations:
– World Health Organization (WHO): who.int
– International Society on Thrombosis and Haemostasis: isth.org
– National Blood Clot Alliance: stoptheclot.org
– Thrombosis UK: thrombosisuk.org
– European Society of Cardiology: escardio.org
Patient support:
– ClotCare: clotcare.com
– Anticoagulation Forum: acforum.org
Related conditions
Deep vein thrombosis – Blood clots in deep veins, often preceding pulmonary embolism
Chronic thromboembolic pulmonary hypertension – Long-term complication causing elevated lung pressures
Factor V Leiden – Common inherited clotting disorder increasing thrombosis risk
Antiphospholipid syndrome – Autoimmune condition causing recurrent blood clots
Protein C deficiency – Inherited condition affecting natural anticoagulation
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.
Cite this page
GMJ News Desk. “Pulmonary Embolism.” GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/condition/pulmonary-embolism/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?